Scepticism over Boehringer Ingelheim's flibanserin ahead of US advisory panel meeting
This article was originally published in Scrip
Executive Summary
The US FDA's reproductive health drugs advisory committee will meet on 18 June to discuss whether Boehringer Ingelheim should be allowed to market flibanserin for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. There is great scepticism about the drug on the part of agency staffers who reviewed the NDA and their briefing for the panel of outside experts raised doubts about both the efficacy and safety of the compound.